In September 1999, the perceptions of the use of adenoviral (Ad) vectors for gene therapy were altered when a patient exposed via the hepatic artery to a high dose of adenoviral vector succumbed to the toxicity related to vector administration. Appropriately, concerns were raised about continued use of the Ad vector system and, importantly, there were increased efforts to more fully understand the toxicity. Today it is recognized that there is no ideal vector system, and that while Ad vectors are not suitable for all applications, the significant advantages over other vector systems including efficient transduction of a variety of cell types, both quiescent and dividing, make it optimal for certain applications. These include protocols where high levels of short-term expression are sufficient to provide a therapeutic benefit. Potential target applications include therapeutic angiogenesis, administration into immune-privileged sites such as the CNS, or treatments where the adjuvant effect of adenovirus can be of benefit such as cancer vaccines. Broader applicability of Ad vectors will require resolution of toxicity issues. This review will therefore focus on studies conducted over the last 2 years that have advanced our understanding of the toxicity associated with Ad vectors, studies that have employed methods to reduce toxicity and improvements in Ad vectors themselves that will reduce toxicity by one of several mechanisms. These mechanisms include retargeting vector to the tissue of interest, minimizing or eliminating viral gene expression that is thought to result in loss of transduced cells, or by methods that seek to reduce the vector dose required for therapeutic benefit. An area where there remains significant room for improvement is when readministration of vector is required because transgene expression has decreased to background levels.
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Ad vector-induced toxicity is complex
As a reflection of the importance of Ad-induced toxicity, the entire January 2002 issue of Human Gene Therapy
In brief Progress
Application of Ad vectors to select applications such as therapeutic angiogenesis has generated cautious optimism. An understanding of Ad vector-induced toxicity is continuing to grow and is leading to methods to minimize it's effects. Refinements in targeting of Ad vectors are improving the therapeutic index. Advanced generation Ad vectors have reduced toxicity and improved persistence of transgene expression.
Prospects
Methods to reduce toxicity will continue to be advanced and will lead to safer use of Ad vector systems. The use of targeting methods will be improved. Production methods of fully deleted Ad vectors will continue to improve. Further efforts will be focused on readministration challenges. was devoted to the topic. A call by the National Institutes of Health Recombinant DNA Advisory Committee for a better understanding of the toxicity of Ad vectors included recommendations to develop standards, so that data collected by various laboratories can be compared, to develop a database for the collection and organization of safety and toxicity data and several recommendations to improve the safety of research participants. 2 A standard that has been developed includes adenoviral vector reference material that is available to investigators for comparison to their vectors. It is apparent that only with a thorough understanding of all aspects of the toxic interaction between a vector and the host that the full utility of any vector system will be realized. However, the toxicity associated with the use of Ad vectors is extremely complex involving both the innate and adaptive immune responses. It is dose dependent, occurs in phases, is related to route of administration, is dependent on tissue and cell type targeted and varies with species. In addition, the role of the response to a foreign or reporter transgene is often ignored but can complicate interpretation of the findings. Finally, it is important to remember that extrapolations from preclinical studies to clinical studies should take into account that the vast majority of preclinical studies are performed in normal, naïve animals, whereas clinical studies are conducted in a population likely not naïve to adenovirus and that has underlying disease.
The initial response to Ad vectors administered intravascularly occurs within minutes, occurs in the absence of viral gene expression and is attributed to the innate response. Building on earlier studies has shown that, as the vector distributes in the blood, it interacts with cells of the reticuloendothelial system (RES) and induces the release and/or production of several proinflammatory cytokines including IL-6, TNFa, IL-8, GM-CSF and MIP-2.
3,4 Cytokine production appears to occur through the NFkB pathway possibly via Raf/MAP kinase phosphorylation of IkB. 4, 5 Higginbotham et al 4 reported that exposure of normal human peripheral blood mononuclear cells to Ad vector resulted in the release of multiple proinflammatory cytokines in vitro.
The authors suggested that transcriptional stimulation of these cytokines was the result of cellular binding of virions/capsids. In addition to the mechanism described above, Ad vectors have been shown to activate complement in vitro, 6 but the significance of this response has yet to be demonstrated in vivo.
The immediate response peaks around 6 h and the primary cells thought to be responsible are macrophages and dendritic cells that serve as a functional bridge between the innate and acquired immune response. These cells are activated and induced to mature, which results in upregulation of MHC antigens as well as costimulatory and adhesion molecules. 7 The inadvertent targeting of these antigen-presenting cells leads to a systemic acquired immune response. 8 In addition, vector interaction with epithelial cells results in release of C-X-C chemokines, especially IP-10.
5 IP-10 is a potent chemoattractant for activated T lymphocytes and pushes the reaction towards a Th-1 type or cytotoxic T-lymphocyte (CTL) response. Thus, the innate response bridges via multiple pathways with the acquired response that follows.
Subsequent responses or possible sequelae to the initial response can be lethal, can occur within days and can be correlated, at least in part, with Ad gene expression. For the most part, this response has been well characterized and is correlated with the infiltration of lymphocytes, the formation of anti-Ad antibodies and the loss of transduced cells. When a lethal response occurs following administration of high doses, systemic changes have been described that include extensive endothelial damage and disseminated intravascular coagulopathy. 9 Several studies described a decrease in platelets and an increase in the von Willebrand factor. [8] [9] [10] It is of note, however, that Ad vectors do not directly induce platelet aggregation. 11 The January 2002 issue of Human Gene Therapy mentioned above contains two studies describing the responses in nonhuman primates. 9, 12 Studies in nonhuman primates may be the most instructive to our understanding of Ad-mediated toxicity as the responses have been shown to mirror those described in patients. 10 The findings of studies conducted in primates, including humans, are summarized briefly in Table 1 . It is important to note that on balance, other manuscripts in that issue of Human Gene Therapy concluded that in studies using several routes of local administration of low to intermediate doses of Ad vectors were welltolerated in humans. 13, 14 In summary, the toxicity associated with the administration of Ad vectors must be fully appreciated and steps taken to reduce it. An additional complication underscoring the need for treatment to reduce toxic effects, was the demonstration that the physical act of some methods of administration themselves, even in the absence of vector, result in elevated levels of IL-6. 15 A straightforward approach to reduce toxic responses has been the pretreatment or coadministration of anti-inflammatory agents. Pretreatment of animal models with steroids such as dexamethasone and budesonide was shown to decrease transcription of chemokines and cytokines, thereby reducing the innate and downstream-acquired response including production of antibodies to Ad vectors. 16 
Targeting of Ad vectors will improve the therapeutic index
There have been significant efforts in the last 2 years to retarget Ad vectors away from the primary receptor (coxsackie-adenovirus receptor -CAR) to a tissue or cellspecific receptor. The aims are (i) to restrict transduction to the organ of interest, thereby gaining the greatest benefit with the lowest dose, (ii) to minimize the innate response by limiting vector interaction with the RES and (iii) to potentially avoid the effects of an anti-Ad neutralizing antibody response. [17] [18] [19] Another rationale for targeting Ad vectors is that CAR is present in low levels in some cell types that are potential targets for gene transfer.
The most straightforward method of detargeting of CAR binding is to pseudotype human serotypes with capsids from other species [20] [21] [22] or to simply employ Ad vectors from nonhuman serotypes. 23 This approach has the added benefit of avoiding the neutralization of input vector by preexisting antibodies to human adenoviruses. Other targeting approaches are grouped into two categories; those that modify the viral capsid through genetic alteration especially of fiber and fiber knob DNA and those that employ two components where one binds to the Ad vector and is linked to another that will target the complex to a specific receptor. Genetic retargeting of Ad vectors involves the ablation of the normal tropism by mutating or deleting the CAR-binding sequences and incorporating foreign sequences into the loops within the knob of the fiber shaft redirecting the vector to specific receptors on selected cell types. The feasibility of this approach was demonstrated with the identification of a conserved receptor-binding region on the side of three divergent CAR-binding knobs. However, the complexity of the fiber knob is such that modifications may destabilize the fiber with failure to trimerize, rendering the vector nonfunctional. 24 A modified approach therefore incorporated the deletion of the entire knob domain of the adenovirus fiber protein and replacing it with two distinct moieties that provide a trimerization function for the knobless fiber and specific binding to the target cell. 25 These approaches have been tested extensively and demonstrated efficient transduction (up to a three log increase) 26 of the desired targets including endothelial 27 and smooth muscle cells, 22 brain microcapillary bed, 28 synovial cells 29 and tumor cells. 30 A Phase I clinical trial is underway in which an Ad vector genetically modified to target integrins via the Arg-Gly-Asp (RGD) peptide motif is being tested in ovarian cancer and recurrent cancer of the oral cavity. 26 Ablation of native tropism requires the development of additional packaging cell lines and the size of the modifications to the fiber knob is restricted to about 30 amino acids. Even with these limitations and added complexities, the advantages of the single component system are that vector production and qualification for clinical use are more straightforward than the challenges of characterizing the heterogeneous mixture of vector, targeting ligand and vector-binding ligand of a twocomponent system. Advantages of the two-component system are that many receptors can be targeted and there is no need to genetically engineer the vector. A commonly used example of the two-component method employs bispecific antibodies, 31 one to the fiber and the other to a cell receptor expressed for example on tumor cells 32 or cell surface antigen that is upregulated in angiogenic areas of tumors. 33 This approach has been used frequently to demonstrate proof of concept of a given targeting ligand.
In addition to the viral particle targeting methods described above, the use of tissue-'specific' promoters can limit transcription to the tissue of interest. 34 While this approach does not avoid vector interaction with the RES, it has provided an unexpected benefit where in the case of muscle or liver-specific expression, there was no detectable antibody response to the foreign transgene. 35 Transgene expression in these instances was also prolonged.
These are but a fraction of the studies that have been published recently in the area of targeting of Ad vectors and it is clear that this intense effort will advance the field. It will be extremely important to evaluate the modified vectors comprehensively in vivo, as exemplified in the recent report from Smith et al, 36 who demonstrated that it is not sufficient to simply mutate the CAR-binding sites in fiber knob to redirect transduction in vivo. 36 These investigators mutated CAR binding in Ad5 fiber only to discover that upon injection into mice there was increased transduction in the liver with the modified vector. This observation may be related to CAR-independent transduction via heparin sulfate glycosoaminoglycans 37 and may call into question the currently accepted cell entry pathway.
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Advanced generations of Ad vectors provide increased persistence with reduced toxicity
Many applications of gene therapy will require lifelong transgene expression, but most current Ad vectors result in an expression that is transient. Transgene expression is complex with at least three factors that can impact persistence including the expression cassette itself, the immune response to the vector and/or the transgene product and turnover of the transduced cell. The importance of the expression cassette was demonstrated by De Geest et al, 38 who reported that gene transfer with an adenovirus comprising the 256-bp apo A-I promoter, the genomic apo A-I DNA and four apo E enhancers, all of human origin, resulted in human apo A-I expression above 20 mg/dl for up to 6 months in the absence of significant hepatotoxicity. 38 Another study concluded that 'strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo'. 39 These investigators demonstrated that by using a very strong promoter the required dose to achieve sufficient transduction could be reduced 100-fold, thereby reducing the toxicity. However, an often-ignored factor is what impact such a strong expression will have on normal cellular function, and this will likely vary between cell types.
It is widely held that transgene expression will decrease to approximately background levels within 3 weeks following administration of first-generation vectors. However, there are examples of first-generation vectors that provide prolonged expression. 40 In addition, partially deleted vectors have resulted in persistent expression. 41 It is therefore unclear how much of the viral genome must be deleted to achieve the desired length of expression. 42 There may, in fact, be a benefit in retaining some viral genes as they function to modulate the cellular immune response. 43 However, studies characterizing the function of the E4 gene products led the investigators to conclude that it is 'prudent' to remove all of the E4 region. 44 It is important to remember that with each deletion of a viral gene, a cell line must be created to complement that gene 45 and this can create production issues.
Helper-dependent, fully deleted Ad vectors offer great potential
With the recognition that viral gene expression even at low levels can lead to loss of transgene expression, a significant effort is in progress to develop Ad vectors that do not contain any viral genes. These are variously referred to as helper-dependent, high-capacity, gutted or gutless vectors, fully deleted and pseudo-adenovirus (PAV). Although these vectors do not avoid the innate response, many studies have demonstrated reduced toxicity with prolonged expression (for recent review see Kochanek et al 46 ). The helper-dependent (HD) Ad vectors are produced with a helper Ad that provides the necessary viral functions, but cannot be packaged because the packaging signal is excised. This excision is typically mediated by a bacterial phage P1 Cre recombinase that recognizes loxP sites that flank the region essential for packaging. Another approach has been to employ a yeast recombinase (FLPe), where the loxP sites are replaced with FLPe recombinant targets (FRT). 47, 48 Umana et al 47 report greater efficiency with the FLPe recombinase and claim that this should allow large-scale production of HD vectors using column chromatography-based virus purification. A challenge of the HD vector system is that the vector preparations are contaminated with low levels of helper Ad virus. Since the intent is to move away from a vector with any viral genes, there are concerns of what impact the contaminating virus will have on the toxicity and persistence of expression. One study attempted to address this by adding back increasing levels of helper virus and did not detect a decrease in persistence with levels up to 10%. 49 A novel system for the production of HD vectors that does not require helper Ad, and is therefore not contaminated with helper virus, has been described. 50 The adenoviral genes are delivered into producer cells by a baculovirus-adenovirus hybrid, Bac-B4, carrying a Cre recombinase-excisable copy of the packaging-deficient adenovirus genome. Although this resulted in preparations of vectors that were free of contaminating Ad helper, scaling-up was prevented by the eventual emergence of replication-competent adenovirus (RCA). Further optimization of HD vector production that provides increased yields, minimal Ad helper, scalability and minimal levels of RCA has recently been described. 51 HD vectors have been used in a variety of applications with an almost uniform improvement in persistence of transgene expression. Several of these were recently reviewed by Kochanek. 46 For example, lifetime correction of hyperlipidemia was demonstrated in a mouse model. 52 In this study, expression was detected for 2.5 years. In a mouse model of hemophilia, the defect was corrected for greater than 9 months with the expression of factor VIII. 49 Along with the advantages of the increased persistence of transgene expression, HD vectors have a greater capacity of up to 36 kb. Although HD vectors have demonstrated advantages, they remain difficult to produce and purify in clinically relevant quantities and it is clear that advances in this area are still required before products can be introduced into the clinic.
Readministration with Ad vectors remains a challenge
Applications in which lifelong expression is necessary will require readministration of vector following the eventual loss of therapeutic transgene expression. Without intervention or masking of the vector, the neutralizing antibody response to a previous exposure to Ad either through natural infection or administration of vector can preclude or significantly reduce effective readministration. However, several studies have documented effective readministration in certain limited applications. For example, an initial intramuscular administration of low-dose Ad vector producing low but detectable levels of transgene expression did not preclude readministration into the muscle, where systemic readministration was not effective. 53 In a phase I/II trial for recurrent ovarian cancer where intraperitoneal readministration was used, transgene expression was measurable in 17 of 20 samples obtained after two or three cycles. 54 Thus, it should be recognized that the ability to effectively repeat administer Ad vectors is dose-dependent and site-specific.
Since effective intravascular readministration in the absence of some intervention is unlikely, various approaches are being tested to circumvent the neutralizing response. A popular and straightforward approach that has been tested involves a serotype switch such that the second administration would not encounter a neutralizing response. 55 There are, however, a finite number of serotypes and this approach would represent a complex set of clinical products. An intriguing approach attempts to physically remove the neutralizing antibodies. Plasmapheresis is a clinical procedure commonly used to reduce the antibody levels in patients with some autoimmune conditions. A method similar to this clinical practice was used to remove anti-Ad antibodies from serum by affinity chromatography and the resulting eluate was tested both in vivo and in vitro for neutralization capacity. 56 These authors reported that depletion of antiadenoviral antibodies restores transduction in vivo during systemic Ad gene therapy in hosts previously exposed to adenovirus. Although this approach shows promise, it remains to be determined to what level the antibodies must be reduced and whether this is feasible in humans. Another approach has involved the masking of vectors to both reduce the response to the initial Ad treatment and evade the neutralizing response on subsequent exposures. Studies have employed a variety of molecules including polyethylene glycol polymers, 57 multivalent hydrophilic polymers that can incorporate targeting ligands in addition to masking the vector 58 and bilamellar cationic liposomes. 59 These methods have potential, but remain to be fully characterized in terms of toxicity.
Immune intervention or modulation has also been used to avoid or minimize the neutralizing immune response. This approach seeks to minimize the response to the first Ad vector exposure, thereby permitting subsequent administrations. A straightforward approach involves pretreatment or coadministration of anti-inflammatory drugs such as steroids. 16 A more complex method involves the administration of monoclonal antibodies directed against costimulatory signalling molecules that are required for the development of a fully mature immune response. One such approach employed antibodies directed against CD40, CD80/B7.1 and CD86/B7.2. 60 This treatment reportedly fully abrogated the immune response against the Ad vector such that readministration was as effective as that in naïve animals. In addition, these authors claimed that the animals were capable of mounting a normal response to Ad. Another complex approach incorporates genes into the vector that upon expression will attenuate the immune response. This method was tested using two genes that block costimulatory signals that are required for an optimal immune response. 61, 62 These authors report that the immunomodulatory genes CTLA4Ig and CD40Ig included in one HD vector and coadministered with an Ad vector coding for a reporter gene resulted in higher levels of transgene expression, lower levels of anti-Ad antibody and more prolonged transgene expression, when compared to controls. However, prolonged expression of these immunomodulatory genes compromised the host immune response. Other investigators have incorporated the immune modulatory gene CTLA4Ig into the vector containing the transgene of interest and claimed that this vector was more effective in suppression of the immune response than the twovector system. 63 They speculated that high levels of local expression may be required to completely block both humoral and cellular responses.
Summary
Although the utility of Ad vectors for use in clinics has been seriously challenged in the last 2 years, they remain viable, if not preferred, candidates for some gene therapy applications. With a better understanding of the toxic response to Ad vectors, investigators have begun to utilize a variety of methods to attenuate or avoid this potentially lethal response. Future Ad vectors incorporating features outlined in this review would be fully deleted nonhuman Ads, modified to target away from the RES in favor of the organ of interest and carry, in addition to the gene of interest under control of a tissuespecific promoter, controllable immunomodulatory gene(s) that would attenuate the immune response.
